Moderna, a biotech company, has reported positive early results for a potential coronavirus vaccine. The company partnered with the National Institutes of Health (NIH) in order to develop the vaccine.
The biotech and NIH started their work on a coronavirus vaccine in early January. The organizations created vaccine candidates with only the genetic code of COVID-19.
These early results come from its Phase 1 clinical trial. The trial findings are based on the results from eight people, each of whom received two doses of the experimental vaccine. The subjects all reportedly exhibited healthy results. The intention of the trial was to determine the safety of the vaccine and see whether there was presence of an immune response or not. While the vaccine did stimulate an immune response against COVID-19, the results did not show whether the vaccine would prevent infection. In addition, Moderna is continuing to conduct Phase 1, as two more ages groups (55 to 70, and 71 and over) have not been tested.
Moderna’s next steps include the beginning of a mid-stage study, with a late-stage trial in July. The intention is for a ready-for-use emergency vaccine by fall, despite the fact that this timeline has never been completed in the history of vaccine development. If it works, their vaccine would be seeking full regulatory approval in 2021.